Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) increased considerably to $6.27. It was posted on Apr, 2 by Barchart.com. The company has $132.20 million market cap. At $6.46 stock PT, the company valuation changes by $3.97M more.

For more Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) news published briefly go to: Nasdaq.com, Benzinga.com, Seekingalpha.com, Benzinga.com or Investorplace.com. The titles are as follows: “Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights – Nasdaq” published on March 11, 2019, “31 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” on March 21, 2019, “ZYNE, MXWL among premarket gainers – Seeking Alpha” with a publish date: February 04, 2019, “Zynerba’s Patent Win Sends Cannabis Biotech’s Shares Higher (NASDAQ:ZYNE) – Benzinga” and the last “5 Cannabis Stocks Set to Skyrocket — According to Wall Street’s Top Analysts – Investorplace.com” with publication date: April 02, 2019.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.The firm is valued at $132.20 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain.Last it reported negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.